Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04525014 · ClinicalTrials.gov registry record · Phase 1
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
A Phase 1 study, sponsored by EpicentRx.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04525014 is a Phase 1 study that was terminated before completion, run by EpicentRx. The registered enrollment target is 2 participants.
The verdict
NCT04525014, a Phase 1 study, was terminated before completion, sponsored by EpicentRx.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults. However, the investigators do not know what effects it will have in children and young adults.
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG RRx-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-01-26 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04525014
The ClinicalTrials.gov registry entry for NCT04525014 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT04525014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04525014 about?
NCT04525014 is a clinical study titled "RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors". The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults. However, the investigators do not know what effects it will have in children and y...
What is the current status of trial NCT04525014?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-01-26. Estimated completion is 2024-07-29.
What interventions are being tested in trial NCT04525014?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), RRx-001 (DRUG).
Who is sponsoring clinical trial NCT04525014?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.